Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients. (2014). Farmeconomia. Health Economics and Therapeutic Pathways, 15(4), 101-112. https://doi.org/10.7175/fe.v15i4.971